Positive results from US-veteran mental health trial
Filed with ASX · · 3 pages · English
Summary by 6ix AI
TrivarX Limited reports positive results from a clinical trial aimed at detecting depression symptoms in veterans using its single-lead technology. Results indicate a significant prevalence of depression and PTSD among veterans, highlighting the need for effective screening tools. The findings support TrivarX's commercial positioning and align with veteran mental health priorities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from TrivarX
- TRI Exercises Option to Advance Acquisition of Stabl-Im
- September 2025 Quarterly Activities Report and Appendix 4C
- US-veteran mental health trial patient recruitment complete
- Acquisition of Stabl-Im technology and Private Placement
- Reinstatement to Official Quotation
Later from TrivarX
- December 2025 Quarterly Activities Report and Appendix 4C
- Appendix 4D & Half-Year Financial Report to 31 December 2025
- Dr Danielle Meyrick appointed as CEO
- March 2026 Quarterly Activities Report and Appendix 4C
- CRO Engaged to Advance Stabl-Im Phase 1 Trial
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX